Bhattacharya, U.;                     Kamran, M.;                     Manai, M.;                     Cristofanilli, M.;                     Ince, T.A.    
        Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers 2023, 15, 332.
    https://doi.org/10.3390/cancers15020332
    AMA Style
    
                                Bhattacharya U,                                 Kamran M,                                 Manai M,                                 Cristofanilli M,                                 Ince TA.        
                Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers. 2023; 15(2):332.
        https://doi.org/10.3390/cancers15020332
    
    Chicago/Turabian Style
    
                                Bhattacharya, Udayan,                                 Mohammad Kamran,                                 Maroua Manai,                                 Massimo Cristofanilli,                                 and Tan A. Ince.        
                2023. "Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide" Cancers 15, no. 2: 332.
        https://doi.org/10.3390/cancers15020332
    
    APA Style
    
                                Bhattacharya, U.,                                 Kamran, M.,                                 Manai, M.,                                 Cristofanilli, M.,                                 & Ince, T. A.        
        
        (2023). Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers, 15(2), 332.
        https://doi.org/10.3390/cancers15020332